Picture loading failed.

Anti-Ganglioside GD2 therapeutic antibody (Pre-made Lorukafusp biosimilar,Whole mAb Fusion) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).



Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-322-1mg 1mg 3090
GMP-Bios-ab-322-10mg 10mg 21890
GMP-Bios-ab-322-100mg 100mg 148000
GMP-Bios-ab-322-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-Ganglioside GD2 therapeutic antibody (Pre-made Lorukafusp biosimilar,Whole mAb Fusion)
INN Name Lorukafusp
TargetGanglioside GD2
FormatWhole mAb Fusion
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4tuj:CD:AB/4tul:HL/4trp:HL/4tuo:CD:AB/4tuk:HL
Year Proposed2018
Year Recommended2019
CompaniesLexigen Pharmaceuticals;Apeiron Biologics;Merck KGaA;University of Wisconsin-Madison
Conditions Approvedna
Conditions ActiveMalignant melanoma;Neuroblastoma
Conditions Discontinuedna
Development Techna